A new approach for cellular immunotherapy of nasopharyngeal carcinoma

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1440-1442

  Smith, Corey ^a   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Adenovirus; EBV; Epitope; HLA; Immunotherapy; Nasopharyngeal carcinoma; T cells

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; EPSTEIN BARR VIRUS ANTIGEN 1; LATENT MEMBRANE PROTEIN 1;

ADVANCED CANCER; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOGENICITY; METASTASIS POTENTIAL; NASOPHARYNX CARCINOMA; NOTE; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; SAFETY; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84886945467     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21286     Document Type: Note

References (9)

1. Ma BB, Chan AT. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther 2006; 6:383-94; PMID:16503855; http://dx.doi.org/10.1586/14737140.6.3.383.
2. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23:8942-9; PMID:16204009; http://dx.doi.org/10.1200/JCO.2005.02.6195.
3. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, et al. Adoptive transfer of EBVspecific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010; 33:983-90; PMID:20948438; http://dx.doi.org/10.1097/CJI.0b013e3181f3cbf4.
4. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood 2005; 105:1898-904; PMID:15542583; http://dx.doi.org/10.1182/blood-2004-07-2975.
5. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66:2689-97; PMID:1313894.
6. Smith C, Beagley L, Khanna R. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin- 1-mediated suppression. J Virol 2009; 83:6192-8; PMID:19357166; http://dx.doi.org/10.1128/JVI.00239-09.
7. Smith C, Wakisaka N, Crough T, Peet J, Yoshizaki T, Beagley L, et al. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBVencoded oncogene LMP-1 through self-aggregation. Blood 2009; 113:6148-52; PMID:19372256; http://dx.doi.org/10.1182/blood-2009-02-203687.
8. Smith C, Cooper L, Burgess M, Rist M, Webb N, Lambley E, et al. Functional reversion of antigenspecific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol 2006; 177:4897-906; PMID:16982932.
9. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012; 72:1116-25; PMID:22282657; http://dx.doi.org/10.1158/0008-5472.CAN-11-3399.